ARTIS Ventures Acquires Landmark Bio to Scale Therapy Manufacturing

April 2025 – ARTIS Ventures, a venture capital firm headquartered in San Francisco with a focus on life sciences and biotech innovation, has announced the acquisition of Landmark Bio, a Massachusetts-based biomanufacturing center specializing in cell and gene therapy (CGT). The acquisition enhances ARTIS’s advanced therapy manufacturing capabilities and strengthens its role in the rapidly expanding CGT ecosystem.

Founded as a public–private partnership, Landmark Bio provides GMP-grade biomanufacturing and translational development services to support novel biologics from early-stage research through clinical application. This acquisition allows ARTIS to accelerate its support for high-growth CGT companies by removing critical infrastructure barriers.

According to NextGen Intelligence Stats, the cell and gene therapy manufacturing market is projected to grow significantly through 2030, driven by increased regulatory approvals, a surge in personalized medicine, and heightened investor interest. Scalable and compliant production infrastructure is becoming essential for moving therapies from lab to patient.

Through this acquisition, ARTIS Ventures aims to:

• Expand its biomanufacturing capabilities to reduce bottlenecks in therapy development
• Enable faster time-to-clinic for novel treatments in oncology, rare diseases, and regenerative medicine
• Integrate Landmark Bio into its broader platform-driven biotech ecosystem

The transaction is expected to close in the third quarter of 2025, pending customary regulatory approvals. Landmark Bio will continue to operate under its existing name but as a strategic manufacturing hub within ARTIS’s growing therapeutic innovation network.

Explore detailed market insights and forecasts here:
👉 Cell and Gene Therapy Manufacturing Market – NextGen Intelligence Stats